References:
[2] Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. New England Journal of Medicine 2020.
[6] Kemp SA, Collier DA, Datir R, Gayed S, Jahun A, Hosmillo M, et al. Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion. medRxiv 2020:2020.12.05.20241927.
[7] Kelleni MT. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management. Pharmacological Research 2020:104874.
[8] Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients. medRxiv 2020:2020.10.31.20223883.
[9] Rocco PRM, Silva PL, Cruz FF, Junior MACM, Tierno PFGMM, Moura MA, et al. Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial. medRxiv 2020:2020.10.21.20217208.
[11] Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomedicine & Pharmacotherapy 2021;133:110982.
[12] Atzeni F, Masala IF, Sarzi-Puttini P. A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. Pain and Therapy 2018;7(2):163-77.
[13] Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Pediatric Anesthesia 2008;18(10):915-21.
[14] Kelleni MT. ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. Inflammopharmacology 2020.
[15] Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C. Does Ibuprofen Worsen COVID-19? Drug safety 2020;43(7):611-4.
[16] Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clinical Microbiology and Infection.
[17] Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 2020;17(9):e1003308.
[18] Castro VM, Ross RA, McBride SMJ, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. medRxiv 2020:2020.04.11.20061994.
[20] Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg Chem 2020;104:104257-.
[21] Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, García CH, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020:2020.10.15.20209817.
[22] Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 2020;396(10259):1345-52.
[23] Mina Kelleni. Tocilizumab, Remdesivir and Favipiravir repurposed for COVID-19: The Good, The Bad and The Ugly. , 2020, November 30.
[24] Hu H-R. Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report. Drug Saf Case Rep 2019;6(1):6-.
[26] Li M, Chen P, Yuan Q, Song B, Ma J. Transmission characteristics of the COVID-19 outbreak in China: a study driven by data. medRxiv 2020:2020.02.26.20028431.
[28] Hong W, Chen Y, You K, Tan S, Wu F, Tao J, et al. Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study. Frontiers in Pharmacology 2020;11(1795).